Goldman Sachs Amends Atara Bio Stake on Dec 29
Ticker: ATRA · Form: SC 13G/A · Filed: Feb 6, 2024 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | SC 13G/A |
| Filed Date | Feb 6, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, biotechnology
TL;DR
**Goldman Sachs changed its stake in Atara Bio, watch for market reaction.**
AI Summary
Goldman Sachs Group Inc. filed an amended SC 13G/A on February 6, 2024, indicating a change in their beneficial ownership of Atara Biotherapeutics, Inc. common stock as of December 29, 2023. This filing, an amendment to a previous disclosure, signals that Goldman Sachs's stake in Atara Biotherapeutics has either increased or decreased, which is important for investors as large institutional movements can influence stock price and reflect confidence (or lack thereof) in the company's future prospects.
Why It Matters
Large institutional investors like Goldman Sachs adjusting their holdings can signal shifts in their outlook on Atara Biotherapeutics, potentially influencing other investors' decisions and the stock's performance.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of ownership changes by a large institution and doesn't inherently indicate high risk, though the underlying reason for the change could be significant.
Analyst Insight
An investor should investigate the specific details of Goldman Sachs's ownership change (increase or decrease in shares) in the full filing to understand the potential implications for Atara Biotherapeutics' stock and consider if it aligns with their own investment thesis.
Key Players & Entities
- Goldman Sachs Group Inc. (company) — the entity filing the SC 13G/A, reporting a change in beneficial ownership
- Atara Biotherapeutics, Inc. (company) — the subject company whose common stock is being reported on
- December 29, 2023 (date) — the date of the event which required the filing of this statement
- February 6, 2024 (date) — the date the SC 13G/A amendment was filed
- $0.0001 (dollar_amount) — the par value per share of Atara Biotherapeutics' Common Stock
Forward-Looking Statements
- Atara Biotherapeutics' stock price may experience short-term volatility as investors react to Goldman Sachs's adjusted stake. (Atara Biotherapeutics, Inc.) — medium confidence, target: 2024-02-13
FAQ
What type of filing is this document and what does 'Amendment No. 1' signify?
This document is an SC 13G/A filing, which is an amendment to a Schedule 13G. 'Amendment No. 1' indicates that this is the first revision or update to a previously filed Schedule 13G by Goldman Sachs Group Inc. regarding their ownership in Atara Biotherapeutics, Inc.
Who is the 'Reporting Person' in this filing and who is the 'Subject Company'?
The 'Reporting Person' is Goldman Sachs Group Inc., located at 200 West Street, New York, NY. The 'Subject Company' is Atara Biotherapeutics, Inc., located at 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 29, 2023. This is the date when the change in beneficial ownership occurred that triggered the need for this filing.
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box on the cover page.
What is the CUSIP number for the class of securities reported in this filing?
The CUSIP number for the Common Stock, par value $0.0001 per share, of Atara Biotherapeutics, Inc. is 046513107.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 6, 2024 regarding Atara Biotherapeutics, Inc. (ATRA).